[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338959-105":59,"doc-detail-338959-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","next-generation-sequencing-in-lung-cancers-a-single-center-experience-in-taiwan","Next-Generation Sequencing in Lung Cancers - A Single-Center Experience in Taiwan","","Next-generation sequencing (NGS) is increasingly used for biomarker testing in non-small cell lung cancer with expanding targeted therapies. This single-center study evaluates institutional NGS experience using 73 non-small cell carcinoma cases from November 2020 to December 2022. Adenocarcinoma predominated (91.8%), and most patients presented at stage IIIB or beyond (87.7%). EGFR was the most frequently mutated gene (63%), followed by TP53, KRAS, RB1, and CDKN2A. Clinically actionable alterations were found in 75.3%, and 46.1% of actionable or potentially actionable findings resulted in matched therapy.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/next-generation-sequencing-in-lung-cancers-a-single-center-experience-in-taiwan/338959/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/next-generation-sequencing-in-lung-cancers-a-single-center-experience-in-taiwan/338959.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this NGS study in lung cancer?","Question",{"text":112,"@type":113},"To describe the institution’s NGS experience and show how NGS identifies therapeutic targets that may guide treatment strategies in non-small cell lung cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many cases were included and what time period was analyzed?",{"text":117,"@type":113},"A cohort of 73 non-small cell carcinoma cases was identified from the institutional pathology archive between November 2020 and December 2022.",{"name":119,"@type":110,"acceptedAnswer":120},"Which gene mutations were most common in the results?",{"text":121,"@type":113},"EGFR was the most frequently mutated gene (63%), followed by TP53 (50.7%), then KRAS, RB1, and CDKN2A (each 13.7%).",{"name":123,"@type":110,"acceptedAnswer":124},"Did NGS findings lead to matched treatments?",{"text":125,"@type":113},"Yes. After an NGS test, 46.1% of actionable or potentially actionable genetic alterations led to patients receiving a matched therapy.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},338959,1790144530,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","medicina  \nArticle  \nNext-Generation Sequencing in Lung Cancers—A Single-Center Experience in Taiwan  \nWei-An Lai 1,*, Yen-Shuo Huang 1, Kung-Chao Chang 2,3,4, Sheau-Fang Yang 1,3, Chih-Jen Yang 5,6, Yu-Wei Liu 7 and Huan-Da Chen 1  \nCitation: Lai, W.-A.; Huang, Y.-S.; Chang, K.-C.; Yang, S.-F.; Yang, C.-J.; Liu, Y.-W.; Chen, H.-D.  \nNext-Generation Sequencing in Lung Cancers—A Single-Center Experience in Taiwan. Medicina 2024, 60, 236 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)medicina60020236  \nAcademic Editor: Paul Zarogoulidis  \nReceived: 21 December 2023  \nRevised: 18 January 2024  \nAccepted: 25 January 2024  \nPublished: 29 January 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; [eddie83a@gmail.com](eddie83a@gmail.com) (Y.-S.H.)  \n2 Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan  \n3 Department of Pathology, Kaohsiung Medical University Hospital, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan  \n4 Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 80708, Taiwan  \n5 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan  \n6 School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan  \n7 Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80708, Taiwan  \n* [Correspondence: weian930@gmail.com](Correspondence: weian930@gmail.com)  \nAbstract: Background and Objectives: Lung cancer is a leading cause of cancer mortality in Taiwan. With rapid advancement of targeted therapeutics in non-small cell lung cancers, next-generation sequencing (NGS) is becoming an important tool for biomarker testing. In this study, we describe institutional experience of NGS analysis in non-small cell carcinoma (NSCLC) . Materials and Methods: A cohort of 73 cases was identified from the institutional pathology archive in the period between November 2020 and December 2022 . Results: Adenocarcinoma was the most common histologic type (91.8%) . Most patients presented with stage IIIB and beyond (87.7%) . Twenty-nine patients (39.7%) were evaluated at the time of initial diagnosis, while the others had received prior chemotherapy or targeted therapy. The most frequently mutated gene was EGFR (63%), and this was followed by TP53 (50.7%), KRAS (13.7%), RB1 (13.7%), and CDKN2A (13.7%) . Clinically actionable mutations associated with a guideline-suggested targeted therapy were identified in 55 cases (75.3%) overall, and in 47.1% of cases excluding EGFR TKI-sensitizing mutation. Biomarkers other than EGFR TKIsensitizing mutations were compared. Cases without TKI-sensitizing EGFR mutation had more level 1 or 2 biomarkers (excluding EGFR TKI-sensitizing mutations) than cases with TKI-sensitizing EGFR mutations (47.1% versus 20.1%, p = 0.016) . Progressive disease was associated with co-occurrence of clinically actionable mutations (20.5% versus 0%, p \u003C 0.05) . Eight of the nine cases with co-occurring actionable genetic alternations had an EGFR mutation. After an NGS test, 46.1% of actionable or potentially actionable genetic alternations led to patients receiving a matched therapy. Conclusions: Our study demonstrated that NGS analysis identifies therapeutic targets and may guide treatment strategies in NS","cbCaiqMkVE0n32q9","https://ap.wps.com/l/cbCaiqMkVE0n32q9","pdf",1349418,12,"English","# Abstract\n## Background and Objectives\n## Materials and Methods\n## Results\n## Conclusions\n# 1. Introduction\n## Epidemiology and clinical context in Taiwan\n## Biomarker testing and molecular targets","[{\"question\":\"What is the main purpose of this NGS study in lung cancer?\",\"answer\":\"To describe the institution’s NGS experience and show how NGS identifies therapeutic targets that may guide treatment strategies in non-small cell lung cancer.\"},{\"question\":\"How many cases were included and what time period was analyzed?\",\"answer\":\"A cohort of 73 non-small cell carcinoma cases was identified from the institutional pathology archive between November 2020 and December 2022.\"},{\"question\":\"Which gene mutations were most common in the results?\",\"answer\":\"EGFR was the most frequently mutated gene (63%), followed by TP53 (50.7%), then KRAS, RB1, and CDKN2A (each 13.7%).\"},{\"question\":\"Did NGS findings lead to matched treatments?\",\"answer\":\"Yes. After an NGS test, 46.1% of actionable or potentially actionable genetic alterations led to patients receiving a matched therapy.\"}]","Next-Generation Sequencing in Lung Cancers - A Single-Center Experience in Taiwan | PDF",1790026809,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/918fc4600929f19a5a63a48e4595bf32.webp",983,1390,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2df4ef1478ef386e1b70a290a2a8b9a2.webp",982,1388,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e9ab1d59ba9d86e6fe87a7dcffb8372.webp",981,1387,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd90fdaa7a2915500d1013707763dfbc.webp",980,1385]